Fw: HIV Treatment Bulletin [HTB], Volume 12 Number 7/8, July/August 2011

[Guest guest]

From: "i-Base Publications" <i-base_publications@...>Date: Tue, 16 Aug 2011 16:04:17 +0100<nelsonvergel@...>Reply i-base_publications@...Subject: HIV Treatment Bulletin [HTB], Volume 12 Number 7/8, July/August 2011Dear SubscriberAttached to this email is the HIV Treatment Bulletin [HTB], Volume12, Number 7/8, July/August 2011. The online version isavailable at: http://i-base.info/htb/date/2011/08This issueleads with the most important and exciting research from the IASconference in Rome and the 3rd International Workshop on HIV Pediatricsimmediately preceding it. Our reports in this issue include an overview ofthe conference in the Introduction. We conclude ourreports form the BHIVA and CROI meetings this year and include excitingnews on treatment access due to Gilead entering an agreement with theMedicines Patent Pool.Last month wesend out the supplement of this issue, HIV i-Base TAG Pipeline Report 2011,and this is accessible through this issue of HTB. EditorialVolume 12 Number 7/8 July/August 2011Special reportsHTB SUPPLEMENT: 2011 pipeline reportConference reports6thIAS Conference on HIV Pathogenesis, Treatment and Prevention 17–20July 2011, RomeWebcasts for major research at IASTreatment is prevention: ARV treatment in HPTN-052 reducestransmission by at least 96%: single transmission in treatment armoccurred prior to viral suppressionDaily oraltenofovir/FTC PrEP reduces heterosexual transmission by 63% in the TDF2studyTenofovir/FTC vstenofovir as daily oral PrEP: preliminary results from PartnersPrEPElvitegravir vsraltegravir: 48 week results in treatment-experiencedpatientsDolutegravir: 48 weekresults from phase II study in treatment-naïvepatientsLersivirine:48 week results compared to efavirenz in phase 2 treatment-naïvestudyMaraviroc plus atazanavir/rwithout nukes versus standard of care: 48 week resultsSPARTACtrial: treatment in primary infection for 48 weeks shows small delay indisease progressionHearing loss not associated with HIV in MACSand WIHS cohortsPharmacokinetics of darunavir and fosamprenavirin pregnancyLow birth weight and preterm deliveryHormonal contraception and HIV transmissionriskNo difference inAIDS-free survival in children starting ART with a CD4% between15%–24% compared to deferring until less than 15% in the PREDICTtrialPaediatric antiretroviral pipeline:update on etravirine and maravirocPrematurity not associated with earlymortality in infants on ARTMore metabolicabnormalities in children receiving a PI compared to NNRTI in NEVERESTstudyFree online resourcefor treatment decisions without access to genotype resistancetests17thAnnual Conference of the British HIV Association (BHIVA) 6–8 April2011, BournemouthTreatment in seroconversion maintains HIV specific immuneresponses similar to long term slow progressors18th Conference on Retroviruses and Opportunistic Infections (CROI)27 February–3 March 2011, BostonMonitoring treatment in resource limited settings: results fromPHPT-3 and Stratall ANRS12110/ESTER trialsDART: high rates of viralsuppression after five years and a single CD4 test with a threshold of 250cells/mm3 could reduce unnecessary switchingLopinavir/r monotherapyused as second-line therapy in resource-limited settingsTreating children previously exposed to single dose nevirapine:update on IMPAACT P1060 and NEVERESTLopinavir/ritonavir oral solution toxicity inneonatesPaediatric antiretroviral pipeline: darunavirand raltegravirPharmacokinetics of different rifabutin dosing strategies withlopinavir/ritonavir-based ARTInitiation of ARTduring breastfeeding can induce multidrug resistance ininfantsAntiretroviralsFDA approve new NNRTI rilpivirine (Edurant) in theUSFDAapprove new NNRTI-based fixed dose combination of rilpivirine/tenofovir/FTC(Complera) in the USHepatitis coinfectionFDA approve boceprevir (Victrelis) for HCVFDA approve telaprevir (Incivek) to treat hepatitisCFDA supplemental information about usingboceprevir and telaprevirPK and drug interactionsDolutegravir (S/GSK1349572) withmultivitamins or acid reducing agentsLopinavir and rifampicin interactionin HIV-positive patientsCase Reports –Cushing’s syndrome with atazanavir/ritonavirTreatment accessGilead signs up for Medicines Patent PoolFDAapproval of generic ARVsTransmission and preventionHPTN 052 study stopped early: significantreduction in HIV transmission from early use of HIV treatment inserodifferent partnersOn the webTreatment as prevention: onlinepresentationsCCR5tropism guidelinesUN High Level Meeting on HIV and AIDSFuture meetings2011-2012 conference listingIntroduction tocombination therapy July 2010 [830 Kb]http://i-base.info/home/introduction-to-combination-therapy-july-2010-edition/Guide toChanging Treatment and Drug Resistance [780Kb]http://i-base.info/home/new-guide-to-changing-treatment-drug-resistance/HIV and yourquality of life: a guide to side effects and other complications December2010 [1.2Mb]http://i-base.info/guides/sideHIV, pregnancy & women's health January 2009 [364 Kb]http://i-base.info/guides/pregnancyHepatitis C for Peopleliving with HIV March 2009 [887 Kb]http://i-base.info/guides/hepcIf you would like to orderadditional hard copies please order online using the form at the followingaddress:http://www.i-base.info/forms/order.phpFinally, if you wish toamend or delete your subscription please use the form at the followingaddress:http://www.i-base.info/forms/index.htmlKind Regards,AngelineMarangSubscription ManagerHIV i-Base4th Floor57 Great SuffolkStreetLondonSE1 0BBClickhere to unsubscribe